Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk

The latest update is out from Atossa Therapeutics ( (ATOS) ).

On February 17, 2026, Atossa Therapeutics, Inc. announced it had regained compliance with Nasdaq’s minimum closing bid price rule, resolving a deficiency first flagged on February 21, 2025, when its stock traded below $1.00 for 30 consecutive business days. After receiving an initial compliance deadline of August 20, 2025, and a subsequent 180‑day extension to February 17, 2026, the company satisfied the requirement by maintaining a closing bid price of at least $1.00 for 10 straight trading days as of February 13, 2026, ensuring its shares will remain listed on The Nasdaq Capital Market and averting potential delisting risk for investors.

The most recent analyst rating on (ATOS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Atossa Therapeutics stock, see the ATOS Stock Forecast page.

Spark’s Take on ATOS Stock

According to Spark, TipRanks’ AI Analyst, ATOS is a Neutral.

The score is held down primarily by weak financial performance (no revenue, ongoing losses, and rising TTM cash burn) and a strongly bearish technical setup (price far below key moving averages with negative MACD). Positive FDA-related corporate milestones provide some support, but valuation is difficult to justify with negative earnings and no dividend.

To see Spark’s full report on ATOS stock, click here.

More about Atossa Therapeutics

Atossa Therapeutics, Inc. is a biotechnology company whose common stock is listed and traded on The Nasdaq Capital Market. The company operates in the life sciences sector and is subject to Nasdaq’s listing standards, including minimum bid price requirements that govern the continued eligibility of its shares for trading on the exchange.

Average Trading Volume: 137,170

Technical Sentiment Signal: Sell

Current Market Cap: $36.17M

For an in-depth examination of ATOS stock, go to TipRanks’ Overview page.